This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's Tecentriq Gets Priority Review for Breast Cancer
by Zacks Equity Research
Roche's efforts to expand the label of its immuno-oncology drug Tecentriq advances as the FDA accepts its sBLA and grants priority review for the treatment of breast cancer.
Top Analyst Reports for Chevron, Novartis & Qualcomm
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Novartis (NVS) and Qualcomm (QCOM)
Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe
by Zacks Equity Research
Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.
Ligand (LGND) Beats on Q3 Earnings & Revenues, Raises View
by Zacks Equity Research
Ligand (LGND) beats earnings and sales estimates in the third quarter of 2018 and raises full-year guidance for the second straight quarter.
Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
by Zacks Equity Research
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3
by Zacks Equity Research
Mylan's (MYL) Q3 revenues lag estimates due to persistent challenges in the North America segment.
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.
Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.
Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates
by Zacks Equity Research
Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.
AbbVie's (ABBV) Q3 Earnings Beat Estimates, 2018 EPS View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings top estimates while revenues fall short. Revenues increase year over year on strong sales growth of Humira, Imbruvica and Mavyret.
Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.
Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View
by Zacks Equity Research
Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.
Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
Aduro's loss (ADRO) betters estimates in Q3. However, lower license and collaboration fees induce a dip in year-over-year revenues.
Amgen (AMGN) Beats on Earnings & Sales in Q3, Raises View
by Zacks Equity Research
Amgen (AMGN) beats estimates for both earnings and sales in Q3 and raises guidance for the full year
Incyte (INCY) Misses on Q3 Earnings & Revenues, Updates View
by Zacks Equity Research
Incyte (INCY) third-quarter earnings and revenues miss estimates but rise year over year.
Pharma Stock Roundup: MRK, BMY Q3 Earnings, Cancer Data Presentations at ESMO
by Zacks Equity Research
Merck (MRK) and Bristol-Myers (BMY) report mixed third-quarter results. Pharma bigwigs present cancer data at ESMO.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) is expected to see strong sales in its Vaccines business segment.
Gilead (GILD) Beats on Q3 Earnings & Sales, Updates View
by Zacks Equity Research
Gilead's (GILD) third-quarter results beat estimates. However, persistent decline in HCV sales is disappointing.
Incyte (INCY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.
Drug Stocks' Earnings Due on Oct 25: MRK, BMY, GILD & CELG
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their third-quarter results on Oct 25. Let???s take a look at how these companies are poised ahead of their earnings release.
Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT
by Zacks Equity Research
Three biotech stocks are scheduled to release their third-quarter results on Oct 24. Let's take a look at how these companies are poised ahead of their earnings release.
Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.
BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store?
by Zacks Equity Research
We take a look at some of the key factors of the two biotech stocks scheduled to release their third quarter results on Oct 23.
Novartis Reports Positive Long-Term Data From Cosentyx Trials
by Zacks Equity Research
Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications.